Major projects and Funders
FUTURE INVESTMENT PROGRAMS (PIA)
LabEx LipSTIC
The Laboratory of Excellence LipSTIC (for Lipoproteins and Health: Prevention and Treatment of Inflammatory Diseases and Cancer / LabEx, ANR-11-LABX-0021) focuses on lipoproteins as a vector for the transport of drugs or biologically active substances (fat-soluble vitamins, lipopolysacharides), or as a biological biomarker in chronic inflammatory pathologies (excluding atherosclerosis) and cancer. RIGHT coordinates the LabEX which includes 23 laboratories and 4 biotechs.
SFRI InteGrate UBFC/Graduate School INTHERAPI
RIGHT participates in this SFRI, and more particularly, in the Graduate School (GS) dedicated to Health. One of the members of the unit, Professor Yann Godet, is deputy coordinator of the GS INTHERAPI.
Two areas of this GS overlap with the unit’s themes: cancer immunotherapy and targeted treatments in inflammatory diseases.
RIGHT is involved in the training of future researchers.
Projet européen FEDER de Spécialisation Intelligente (RI3S)
BioImp
A consortium bringing together academic and industrial players specialized in bioproduction, biotechnology, and microtechnology—including Cellquest, Diaclone, the EFS, FC’Innov, Med’In’Pharma, RD Biotech, as well as the University Marie and Louis Pasteur with its two laboratories Femto-ST and RIGHT—joined forces in 2023 to launch the BioImp project (BIOPROCESSES IMPROVEMENT). This ambitious initiative aims to design and implement innovative technological and biotechnological solutions to optimize the manufacturing processes of biopharmaceuticals.
Institut CARNOT OPALE
The Carnot Institutes aim to develop partnership research, i.e. partnerships between academic teams and industrial partners.
RIGHT participates in the Carnot Institute OPALE aiming to develop partnership research on leukemia. RIGHT participates through its research on the understanding of leukemias derived from plasmacytoid dendritic cells (or BPDCN, for blastic plasmacytoid dendritic cell neoplasm), or the pathophysiology of graft-versus-host disease (or GVH, a major complication of one of the treatments for leukemias, allogeneic transplantation of hematopoietic cells), and the development of CAR-T cells (IL-1RAP or CD123).
FUNDERS
